Objectives: To provide an evidence-based practice overview on the clinical use of
bromocriptine-quick release (QR) across the natural history of type 2 diabetes mellitus …

OBJECTIVE Quick-release bromocriptine (bromocriptine-QR), a D2 dopamine receptor
agonist, is indicated as a treatment for type 2 diabetes. The Cycloset Safety Trial, a 52-week …

Importance to the field: There is a large unmet need for new therapies to treat type 2
diabetes (T2DM) which reduce fasting and postprandial glucose without increasing insulin …

Quick-release bromocriptine (bromocriptine-QR)(Cycloset) was approved in 2009 for the
treatment of type 2 diabetes. The exact anti-diabetic mechanism of action of bromocriptine …

Type 2 diabetes mellitus (T2DM) continues to rise in prevalence in the United States and
worldwide. Despite advances in medical treatments for T2DM, many patients remain …

Introduction Bromocriptine mesylate quick release (QR) is a dopamine D2 receptor agonist
and is the only oral, primarily centrally acting drug that can be used for the treatment of …

Objective To review available data on the efficacy and safety of bromocriptine-QR (BQR)
and to consider its role in the management of Type 2 diabetes mellitus (T2DM). Methods …

An extended series of studies indicate that endogenous phase shifts in circadian neuronal
input signaling to the biological clock system centered within the hypothalamic …

Background Bromocriptine‐QR (a quick‐release formulation of bromocriptine mesylate), a
dopamine D2 receptor agonist, is a US F ood and D rug A dministrration–approved …

Objective: To review the pharmacologic characteristics, safety, and efficacy of bromocriptine
mesylate for glycemic control in patients with type 2 diabetes mellitus. Data Sources: A …